Treatment of de novo acute myeloid leukemia in the United States: A report from the Patterns of Care program

Leukemia and Lymphoma

Volumn 55, Issue 11, 2014, Pages 2549-2555

  Doria Rose, V Paul ^a   Harlan, Linda C ^a   Stevens, Jennifer ^b   Little, Richard F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Acute myeloid leukemia; Patterns of care; Survival; Treatment

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CD135 ANTIGEN; CYTARABINE; NUCLEOPHOSMIN; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOTRANSPLANTATION; ARTICLE; ASSOCIATION; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; GENE MUTATION; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROMYELOCYTIC LEUKEMIA; UNITED STATES; VERY ELDERLY; ACUTE DISEASE; CLINICAL PRACTICE; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS AND NUMERICAL DATA; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEER PROGRAM; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84912123286     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.885517     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008;19:379-390.
3. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
4. Derolf AR, Kristinsson SY, Andersson TM, et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009;113:3666-3672.
5. Luke C, Nguyen AM, To B, et al. Myeloid leukaemia treatment and survival-the South Australian experience, 1977 to 2002. Asian Pac J Cancer Prev 2006;7:227-233.
6. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008; 93: 594-600.
7. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003; 97: 2229-2235.
8. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Available from: http://seer.cancer.gov/csr/1975-2010/
9. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010;115:453-474.
10. O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011; 9: 280-317.
11. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359.
12. Mayer RJ, Davis RB, Schifer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
13. Frattini MG, Maslak PG. Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy. J Natl Compr Canc Netw 2008; 6: 995-1002.
14. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematol 2009: 385-395.
15. Grimwade D, Hills RK, Moorman AV, et al. Ref nement of cytogenetic classif cation in acute myeloid leukemia: determination of prognostic signif cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
17. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012;120:2963-2972.
18. Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classifcation? Blood 2007;109:431-448.
19. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009;113:1875-1891.
20. Alibhai SM, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 2009;115: 2903-2911.
21. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-4187.
22. Lang K, Earle CC, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2005; 22: 943-955.
23. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162:1597-1603.
24. Overview of the SEER Program. Available from: http://seer. cancer.gov/about/overview.html
25. Adamo MB, Johnson CH, Ruhl JL, et al., editors. SEER Program Coding and Staging Manual. NIH Publication number 13-5581. Bethesda, MD: National Cancer Institute; 2013.
26. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
27. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-1274.
28. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decisionmaking for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513-1522.
29. Mengis C, Aebi S, Tobler A, et al. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003;21:3933-3939.
30. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients < or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005;103:2082-2090.
31. Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012;119:34-43.
32. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945.
33. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-125.
34. National Comprehensive Cancer Network: Acute Myeloid Leukemia (Version 2.2011). Available from: http://www.nccn.org/professionals/physician-gls/pdf/aml.pdf